SEC Form 4 · accession 0001209191-18-029567
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
R Douglas Norby
Director
Period of report
May 9, 2018
Accepted (ET)
May 11, 2018 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 9, 2018 | P | 9,000 | $10.42 | A | 9,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $10.31 to $10.60. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.